Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

ADP receptors--targets for developing antithrombotic agents.

Satya P Kunapuli1, Zhongren Ding, Robert T Dorsam

  • 1Department of Physiology, Temple University Medical School, Philadelphia, PA 19140, USA. spk@temple.edu

Current Pharmaceutical Design
|October 8, 2003
PubMed
Summary

Platelet P2Y12 receptor antagonists are effective antithrombotic drugs. Targeting P2Y12, expressed mainly in platelets, offers a promising therapeutic strategy for thrombosis treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ursodeoxycholic acid inhibits platelet activation and thrombosis via TREM2: Evidence from mouse models and human studies.

British journal of pharmacology·2026
Same author

Exosome-mediated transfer of NOD2 from platelets to monocytes: a novel therapeutic target for atherosclerosis.

Biochemical pharmacology·2026
Same author

A novel noncanonical Src-mammalian STE20-like kinase 1 (MST1)-Akt/glycogen synthase kinase-3β (GSK3β) pathway drives platelet activation and thrombosis.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Platelet RIP2 Limits Dense Granule Release and Thrombosis via DOCK8-Cdc42.

Arteriosclerosis, thrombosis, and vascular biology·2026
Same author

Mutagenicity of EAT-positive NDSRIs in HepaRG spheroids.

NAM journal·2026
Same author

Ursodeoxycholic acid attenuates sepsis-associated platelet dysfunction through TREM2-linked signaling.

International immunopharmacology·2026

Area of Science:

  • Biochemistry
  • Pharmacology
  • Hematology

Background:

  • Platelet activation by adenine nucleotides involves P2Y1, P2Y12, and P2X1 receptors.
  • Coactivation of P2Y1 and P2Y12 receptors is crucial for ADP-mediated platelet aggregation.
  • P2 antagonists are utilized as antithrombotic agents.

Purpose of the Study:

  • To evaluate the therapeutic potential of P2 receptor antagonists, particularly P2Y12 antagonists, for antithrombotic therapy.
  • To compare the efficacy and characteristics of irreversible and reversible P2Y12 antagonists.
  • To explore combination therapies involving P2Y1 and P2Y12 antagonists.

Main Methods:

  • Review of existing literature on P2 receptor antagonists and their antithrombotic effects.
  • Analysis of clinical studies and preclinical data on P2Y12 antagonists like clopidogrel, CS-747, and AR-C series compounds.

Related Experiment Videos

  • Examination of knockout mouse models to assess the role of P2Y1 in hemostasis.

    • Main Results:

    • P2Y12 receptor antagonists are effective antithrombotic agents due to the receptor's specific expression in platelets.
    • Irreversible antagonists (ticlopidine, clopidogrel) and reversible antagonists (AR-C series, cangrelor) demonstrate clinical efficacy.
    • Combination therapy with cangrelor and clopidogrel shows enhanced P2Y12 antagonism.
    • P2Y1 antagonists have limited antithrombotic potential due to widespread P2Y1 expression.
    • P2X1 receptor inhibition has minimal impact on hemostasis.

    Conclusions:

    • P2Y12 receptor antagonists represent a valuable therapeutic strategy for antithrombotic treatment.
    • The development of both irreversible and reversible P2Y12 antagonists provides options for managing thrombosis.
    • Targeting P2Y12 offers a more specific antithrombotic approach compared to P2Y1.
    • Combination therapies may offer superior P2Y12 antagonism for enhanced antithrombotic effects.